No Data
No Data
Press Release: Foghorn Therapeutics Strengthens Leadership Team With Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Jefferies Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $18
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases Under Strategic Partnership With Pfizer
What Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Gain Is Not Telling You
No Data